Avalo Therapeutics (AVTX) News
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
6.76+0.01 (+0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVTX news summary
We found 4 recent headlines mentioning Avalo Therapeutics (AVTX): 1 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, AVTX is up 0.15% at $6.76. The most recent story, "Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)", was published by GlobeNewswire on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Avalo Therapeutics headlines
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)WAYNE, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…GlobeNewswire
- Avalo Therapeutics, Inc. Enters $200,000,000 At-The-Market Offering Program and Terminates Prior AgreementOn November 5, 2026, Avalo Therapeutics, Inc. entered into an agreement with Jefferies LLC with respect to an at-the-market offering program under which the company may issue and sell, from time to…Nasdaq
- Avalo Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and $462.8 million in CashAvalo Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, highlighting cash, cash equivalents and investments of $462.8 million. The company expects its…NasdaqAVTX, LEN.B
- Avalo Therapeutics to Participate in Upcoming Investor ConferencesWAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for…GlobeNewswire